placebo + montelukast

The regimen referred to as **placebo + montelukast** in the context of GlaxoSmithKline (GSK) clinical trials represents a treatment arm where active montelukast is administered alongside a placebo for another investigational drug. This approach is standard in double-blind, double-dummy trial designs, such as those evaluating the 5-lipoxygenase-activating protein (FLAP) inhibitor **GSK2190915** (fiboflapon) for persistent asthma. In these studies, montelukast serves as an active comparator. Montelukast is a selective leukotriene receptor antagonist (LTRA) that binds with high affinity to the cysteinyl leukotriene receptor 1 (CysLT1). By blocking the action of leukotrienes (LTC4, LTD4, and LTE4) released from mast cells and eosinophils, it effectively reduces airway edema, smooth muscle contraction, and the inflammatory processes associated with asthma and allergic rhinitis.

Brand names

Singulair

Other names

Montelukast sodiumPlacebo montelukast